News | January 24, 2025
Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25
PAT after MI is Rs. 41 crore which is 162% increase
PAT after MI is Rs. 41 crore which is 162% increase
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Investment will fund expansion to meet rising demand for CRDMO services
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
Increases speed to market for drug developers working on nucleic acid therapeutics
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Subscribe To Our Newsletter & Stay Updated
